Research Article
No access
Published Online: 14 June 2012

Preliminary Examination of the Reliability and Concurrent Validity of the Attention-Deficit/Hyperactivity Disorder Self-Report Scale v1.1 Symptom Checklist to Rate Symptoms of Attention-Deficit/Hyperactivity Disorder in Adolescents

Publication: Journal of Child and Adolescent Psychopharmacology
Volume 22, Issue Number 3

Abstract

Objective: To validate the attention-deficit/hyperactivity disorder (ADHD) Self-Report Scale (ASRS) v1.1 Symptom Checklist versus the clinician-administered ADHD Rating Scale (ADHD-RS) in adolescents with ADHD. Method: A total of 88 adolescents with ADHD aged 13–17 years participated in the study. The study was completed in one or two visits, 1–9 weeks apart. At each visit, participants completed the ASRS v1.1 Symptom Checklist, after which raters administered the ADHD-RS. Internal consistency of the ASRS v1.1 Symptom Checklist was assessed by Cronbach's alpha (Cronbach's α). Concurrent validity between the scales was assessed using Pearson's correlation coefficients. Item-by-item reliability between the scales was assessed by the Kappa coefficient of agreement. Results: The mean age of participants was 14.9±1.5 SD years. 76.1% (n=67) were male. 73.9% (n=65) were currently receiving medication for ADHD. Internal consistency of ASRS v1.1 Symptom Checklist items was high, with Cronbach's α coefficients of 0.93 at Visit 1 and 0.94 at Visit 2. Pearson's correlation coefficients between the ASRS v1.1 Symptom Checklist and ADHD-RS were highly significant at Visit 1 (r=0.72, p<0.0001) and Visit 2 (r=0.73, p<0.0001). There was moderate item-by-item agreement between individual items on the scales (% agreement: 35.2%–63.4%) with statistically significant kappa coefficients for 17 of the 18 items. Conclusion: The ASRS v1.1 Symptoms Checklist showed high internal consistency and high concurrent validity with the clinician-administered ADHD-RS in adolescents with ADHD. Results of this study suggest that the ASRS v1.1 Symptom Checklist is an internally consistent self-report scale for the assessment of adolescent ADHD and is moderately associated with a concurrently administered clinician measure of ADHD symptoms.

Get full access to this article

View all available purchase options and get full access to this article.

References

Adler LCohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorderPsychiatr Clin North Am27187-2012004. Adler L, Cohen J: Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27:187–201, 2004.
Adler LAShaw DMSpencer TJNewcorn JHHammerness PSitt DJDavidow JVFaraone SV. Reliability of the ADHD Self Report Scale (ASRS) v1.1 Symptom Checklist to Rate Adolescent ADHD SymptomsPaper presented at the 57th Annual Meeting of the American Academy of Child and Adolescent PsychiatryNew York, NY2010. Adler LA, Shaw DM, Spencer TJ, Newcorn JH, Hammerness P, Sitt DJ, Davidow JV, Faraone SV: Reliability of the ADHD Self Report Scale (ASRS) v1.1 Symptom Checklist to Rate Adolescent ADHD Symptoms. Paper presented at the 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry in New York, NY in 2010.
Adler LASpencer TBrown TEHoldnack JSaylor KSchuh KTrzepacz PTWilliams DWKelsey D. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trialJ Clin Psychopharmacol2944-502009. Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D: Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: A 6-month, double-blind trial. J Clin Psychopharmacol 29:44–50, 2009.
Adler LASpencer TFaraone SVKessler RCHowes MBiederman JSecnik K. Validity of pilot adult ADHD self-report scale (ASRS) to rate adult ADHD symptomsAnn Clin Psychiatry18145-1482006. Adler LA, Spencer T, Faraone SV, Kessler RC, Howes M, Biederman J, Secnik K: Validity of pilot adult ADHD self-report scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry 18:145–148, 2006.
Adler LASpencer TFaraone SVReimherr FWKelsey DMichelson DBiederman J. Training raters to assess adult ADHD: reliability of ratingsJ Atten Disord8121-1262005. Adler LA, Spencer T, Faraone SV, Reimherr FW, Kelsey D, Michelson D, Biederman J: Training raters to assess adult ADHD: reliability of ratings. J Atten Disord 8:121–126, 2005.
American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th(DSM-IV).Washington, DCAmerican Psychiatric Association1994. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4thText Revision (DSM-IV-TR).Washington, DCAmerican Psychiatric Association2000. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
Barkley RAAnastopoulos ADGuevremont DCFletcher KE. Adolescents with ADHD: Patterns of behavioral adjustment, academic functioning, and treatment utilizationJ Am Acad Child Adolesc Psychiatry30752-7611991. Barkley RA, Anastopoulos AD, Guevremont DC, Fletcher KE: Adolescents with ADHD: Patterns of behavioral adjustment, academic functioning, and treatment utilization. J Am Acad Child Adolesc Psychiatry 30:752–761, 1991.
Barkley RAFischer MEdelbrock CSSmallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up studyJ Am Acad Child Adolesc Psychiatry29546-5571990. Barkley RA, Fischer M, Edelbrock CS, Smallish L: The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29:546–557, 1990.
Biederman JFaraone SVKeenan KBenjamin JKrifcher BMoore CSprich-Buckminster SUgaglia KJellinek MSSteingard RSpencer TNorman DKolodny RKraus IPerrin JKeller MBTsuang MT. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder, patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samplesArch Gen Psychiatry49728-7381992. Biederman J, Faraone SV, Keenan K, Benjamin J, Krifcher B, Moore C, Sprich-Buckminster S, Ugaglia K, Jellinek MS, Steingard R, Spencer T, Norman D, Kolodny R, Kraus I, Perrin J, Keller MB, Tsuang MT: Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder, patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples. Arch Gen Psychiatry 49:728–738, 1992.
Biederman JFaraone SVMilberger SJetton JGChen LMick EGreene RWRussell RL. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHDJ Am Acad Child Adolesc Psychiatry351193-12041996. Biederman J, Faraone SV, Milberger S, Jetton JG, Chen L, Mick E, Greene RW, Russell RL: Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry 35:1193–1204, 1996.
Biederman JKrishnan SZhang YMcGough JJFindling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group studyClin Ther29450-4632007. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL: Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 29:450–463, 2007.
Biederman JNewcorn JSprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disordersAm J Psychiatry148564-5771991. Biederman J, Newcorn J, Sprich S: Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148:564–577, 1991.
Brown TEAttention-Deficit Disorders and Comorbidities in Children, Adolescents, and AdultsWashington, DCAmerican Psychiatric Press2000. Brown TE: Attention-Deficit Disorders and Comorbidities in Children, Adolescents, and Adults. Washington, DC: American Psychiatric Press; 2000.
Conners CKConners' Rating Scale-Revised: Technical ManualNew YorkMulti-Health Systems, Inc.1997. Conners CK: Conners' Rating Scale-Revised: Technical Manual. New York: Multi-Health Systems, Inc.; 1997.
Cronbach LJ. Coefficient alpha and the internal consistency of testsPsychometrika16297-3341951. Cronbach LJ: Coefficient alpha and the internal consistency of tests. Psychometrika 16:297–334, 1951.
Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorderAmerican Academy of Child and Adolescent PsychiatryJ Am Acad Child Adolesc Psychiatry36Suppl 1085S-121S1997. Dulcan M: Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 36(Suppl 10):85S–121S, 1997.
DuPaul GJGeorge JPower TJAnastopoulos ADADHD Rating Scale—IV: Checklists, Norms, Clinical InterpretationNew YorkThe Guilford Press1998. DuPaul GJ, George J, Power TJ, Anastopoulos AD: ADHD Rating Scale—IV: Checklists, Norms, and Clinical Interpretation. New York: The Guilford Press; 1998.
Faraone SVSergeant JBillberg CBiederman J. The worldwide prevalence of ADHD: Is it an American condition?World Psychiatry2104-1132003. Faraone SV, Sergeant J, Billberg C, Biederman J: The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry 2:104–113, 2003.
Faries DEYalcin IHarder DHeiligenstein JH. Validation of the ADHD Rating Scale as a clinician administered and scored instrumentJ Atten Disord5107-1152001. Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 5:107–115, 2001.
Findling RLChildress ACCutler AJGasior MHamdani MFerreira-Cornwell MCSquires L. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorderJ Am Acad Child Adolesc Psychiatry50395-4052011. Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L: Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 50:395–405, 2011.
Findling RLChildress ACKrishnan SMcGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorderCNS Spectr13614-6202008. Findling RL, Childress AC, Krishnan S, McGough JJ: Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 13:614–620, 2008.
Goodman DWLasser RABabcock TPucci MLSolanto MV. Managing ADHD across the lifespan in the primary care settingPostgrad Med12314-262011. Goodman DW, Lasser RA, Babcock T, Pucci ML, Solanto MV: Managing ADHD across the lifespan in the primary care setting. Postgrad Med 123:14–26, 2011.
Hollingshead ABFour Factor Index of Social StatusNew Haven, CTYale University Press1975. Hollingshead AB: Four Factor Index of Social Status. New Haven, CT: Yale University Press; 1975.
Kaufman JBirmaher BBrent DRao UFlynn CMoreci PWilliamson DRyan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity dataJ Am Acad Child Adolesc Psychiatry36980-9881997. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988, 1997.
Kelsey DKSumner CRCasat CDCoury DLQuintana HSaylor KESutton VKGonzales JMalcolm SKSchuh KJAllen AJ. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trialPediatrics114e1-e82004. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 114:e1–e8, 2004.
Kessler RCAdler LAmes MDemler OFaraone SHiripi EHowes MJJin RSecnik KSpencer TUstun TBWalters EE. The World Health Organization Adult ADHD Self-Report Scale (ASRS): A short screening scale for use in the general populationPsychol Med35245-2562005. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, Howes MJ, Jin R, Secnik K, Spencer T, Ustun TB, Walters EE: The World Health Organization Adult ADHD Self-Report Scale (ASRS): A short screening scale for use in the general population. Psychol Med 35:245–256, 2005.
Kessler RCAdler LBarkley RBiederman JConners CKDemler OFaraone SVGreenhill LLHowes MJ. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey ReplicationAm J Psychiatry163716-7232006. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ: The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716–723, 2006.
Kessler RCGreen JGAdler LABarkley RAChatterji SFaraone SVFinkelman MGreenhill LLGruber MJJewell MRusso LJSampson NAVan Brunt DL. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: Analysis of expanded symptom criteria from the adult ADHD clinical diagnostic scaleArch Gen Psychiatry671168-11782010. Kessler RC, Green JG, Adler LA, Barkley RA, Chatterji S, Faraone SV, Finkelman M, Greenhill LL, Gruber MJ, Jewell M, Russo LJ, Sampson NA, Van Brunt DL: Structure and diagnosis of adult attention-deficit/hyperactivity disorder: Analysis of expanded symptom criteria from the adult ADHD clinical diagnostic scale. Arch Gen Psychiatry 67:1168–1178, 2010.
Mannuzza SKlein RG1999. Adolescent and adult outcomes in attention-deficit/hyperactivity disorder (Trans.)Adolescent and Adult Outcomes in Attention-Deficit/Hyperactivity DisorderH.C. QuayA.E. HoganNew YorkKluwer Academic/Plenum Publishers279-294. Mannuzza S, Klein RG. 1999. Adolescent and adult outcomes in attention-deficit/hyperactivity disorder (Trans.). In: Adolescent and Adult Outcomes in Attention-Deficit/Hyperactivity Disorder. Edited by H.C. Quay, A.E. Hogan. New York: Kluwer Academic/Plenum Publishers; pp. 279–294.
Michelson DFaries DWernicke JKelsey DKendrick KSallee FRSpencer TAtomoxetine ADHD Study Group. Atomoxetine in the treatment of children, adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response studyPediatrics108E832001. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108:E83, 2001.
Millstein RBWilens TEBiederman JSpencer TJ. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHDJ Atten Disord2159-1661997. Millstein RB, Wilens TE, Biederman J, Spencer TJ: Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Atten Disord 2:159–166, 1997.
Murphy KRAdler LA. Assessing attention-deficit/hyperactivity disorder in adults: Focus on rating scalesJ Clin Psychiatry6512-172004. Murphy KR, Adler LA: Assessing attention-deficit/hyperactivity disorder in adults: Focus on rating scales. J Clin Psychiatry 65:12–17, 2004.
Spencer THeiligenstein JHBiederman JFaries DEKratochvil CJConners CKPotter WZ. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorderJ Clin Psychiatry631140-11472002. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140–1147, 2002.
The MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorderArch Gen Psychiatry561073-10861999. The MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073–1086, 1999.
Weiss MJain U. Clinical perspectives on the assessment of ADHD in adolescenceADHD Rep84-102000. Weiss M, Jain U: Clinical perspectives on the assessment of ADHD in adolescence. ADHD Rep 8:4–10, 2000.
Wilens TEMcBurnett KBukstein OMcGough JGreenhill LLerner MStein MAConners CKDuby JNewcorn JBailey CEKratochvil CJCoury DCasat CDenisco MJHalstead PBloom LZimmerman BAGu JCooper KMLynch JM. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorderArch Pediatr Adolesc Med16082-902006a. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM: Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 160:82–90, 2006a.
Wilens TENewcorn JHKratochvil CJGao HThomason CKRogers AKFeldman PDLevine LR. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorderJ Pediatr67696-7022006b. Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, Feldman PD, Levine LR: Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr 67:696–702, 2006b.

Information & Authors

Information

Published In

cover image Journal of Child and Adolescent Psychopharmacology
Journal of Child and Adolescent Psychopharmacology
Volume 22Issue Number 3June 2012
Pages: 238 - 244
PubMed: 22537184

History

Published online: 14 June 2012
Published in print: June 2012
Published ahead of print: 26 April 2012

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Lenard A. Adler
Department of Psychiatry, NYU School of Medicine, New York, New York.
Department of Child and Adolescent Psychiatry, NYU School of Medicine, New York, New York.
Psychiatry Service, VA New York Harbor Healthcare System, New York, New York.
David M. Shaw
Department of Psychiatry, NYU School of Medicine, New York, New York.
Thomas J. Spencer
Department of Psychiatry, Harvard Medical School, New York, New York.
Pediatric Psychopharmacology Research Program, Massachusetts General Hospital, Boston, Massachusetts.
Jeffrey H. Newcorn
Department of Psychiatry, Mt. Sinai School of Medicine, New York, New York.
Paul Hammerness
Pediatric Psychopharmacology Research Program, Massachusetts General Hospital, Boston, Massachusetts.
David J. Sitt
Department of Psychology, Baruch College, New York, New York.
Christina Minerly
Department of Psychology, Hunter College, City University of New York, New York.
Jennifer V. Davidow
Department of Psychiatry, Mt. Sinai School of Medicine, New York, New York.
Stephen V. Faraone
Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York.
Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York.

Notes

Address correspondence to:Lenard A. Adler, M.D.Department of PsychiatryNYU School of Medicine650 First Avenue, 7th FloorNew York, NY 10016E-mail: [email protected]
Findings of this study were presented in part at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, NY, October 2010. This study was funded in part by an investigator-initiated research grant from Eli Lilly and Company, Indianapolis, IN. In compliance with the Uniform Requirements for Manuscripts, established by the International Committee of Medical Journal Editors, Eli Lilly and Company did not impose any impediment, directly or indirectly, on the publication of the study's results. Employees of Eli Lilly and Company were not involved in the study design, in the collection, analysis, and interpretation of data, in the writing of the article, and in the decision to submit the article for publication.

Disclosures

Dr. Lenard Adler has received grant/research support from the following sources: Bristol-Myers Squibb, Shire, Chelsea Therapeutics, Eli Lilly and Company, and the National Institute of Drug Abuse. Dr. Adler has served on the advisory board for AstraZeneca Pharmaceuticals, Eli Lilly and Company, Major League Baseball, Mindsite, Shire, and i3 Research. Dr. Adler has consulted with Abbott Laboratories, AstraZeneca Pharmaceuticals, Cortex Pharmaceuticals, Cephalon, Eli Lilly and Company, Epi-Q, i3 Research, INC Research, Major League Baseball, Merck and Company, Mindsite, Novartis Pharmaceuticals, Organon, Ortho McNeil/Jannsen/Johnson and Johnson, Otsuka Pharmaceuticals, Psychogenics, Sanofi-Aventis Pharmaceuticals, Shire, and United Biosource. Dr. Adler has received royalty payments (as inventor) from the NYU School of Medicine for license of adult ADHD scales and training materials since 2004.
David Shaw has no financial interests or potential conflicts of interest to declare.
Dr. Thomas Spencer has received research support from the following sources: Shire Laboratories, Inc., Cephalon, Eli Lilly and Company, Glaxo-Smith Kline, Janssen, McNeil Pharmaceutical, Novartis Pharmaceuticals, Pfizer, and NIMH. Dr. Thomas Spencer has been a speaker or on a speaker's bureau for the following pharmaceutical companies: Shire Laboratories, Inc., Eli Lilly and Company, Glaxo-Smith Kline, Janssen, McNeil Pharmaceutical, and Novartis Pharmaceuticals. Dr. Thomas Spencer has been an advisor or on an advisory board for the following pharmaceutical companies: Shire Laboratories, Inc., Cephalon, Eli Lilly and Company, Glaxo-Smith Kline, Janssen, McNeil Pharmaceutical, Novartis Pharmaceuticals, and Pfizer.
Dr. Jeffrey Newcorn has received research support from the following sources: Eli Lilly and Company, Ortho-McNeil-Janssen, and Shire Laboratories, Inc. Dr. Newcorn has consulted with Eli Lilly and Company, Ortho-McNeil-Janssen, and Shire Laboratories, Inc. Dr. Newcorn has served on the advisory board for Eli Lilly and Company, Ortho-McNeil-Janssen, Schering-Plough, and Shire Laboratories, Inc.
Dr. Paul Hammerness has received research funds or participated in CME activities/professional talks supported by the following pharmaceutical companies: Abbott, Eli Lilly and Company, Forest, McNeil, and Shire. Dr. Hammerness has also received research funds from Elminda Ltd and has participated in speaker training and served on the advisory board for Shire. Dr. Hammerness has participated, as an investigator, in research studies funded by the following pharmaceutical companies: Abbott, Bristol Myers Squibb, Cephalon, Eli Lilly, Glaxo-SmithKline, Johnson and Johnson, McNeil, Merck, New River, Organon, Pfizer, Shire, and Takeda. Dr. Hammerness has also received honoraria from Reed Medical Education (a logistics collaborator for the MGH Psychiatry Academy). Commercial entities supporting the MGH Psychiatry Academy are listed on the Academy's website, www.mghcme.org.
Dr. David Sitt has no financial interests or potential conflicts of interest to declare.
Dr. Ana Christina Minerly has no financial interests or potential conflicts of interest to declare.
Jennifer Davidow has no financial interests or potential conflicts of interest to declare.
Dr. Stephen Faraone has consulted with, has served the advisory board, or has been a speaker for the following sources: Shire, McNeil, Janssen, Novartis, Pfizer, Ortho-McNeil, and Eli Lilly and Company. Dr. Faraone has received research support from Eli Lilly and Company, Shire, Pfizer, and the National Institutes of Health.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top